YSK4 Inhibitors

YSK4 inhibitors, albeit indirectly extrapolated, encompass a diverse set of chemicals known to influence kinase activities. The intention behind this collection is to capture inhibitors that could affect multiple pathways in which kinases play a pivotal role. Imatinib and Dasatinib, for instance, are tyrosine kinase inhibitors known to target BCR-ABL and several other kinases, reflecting the vast realm of tyrosine kinase pathways. Similarly, Sorafenib, being a multi-kinase inhibitor, highlights the range of receptor tyrosine kinases it can target.

Furthermore, specific inhibitors like JNK Inhibitor II and SP600125, which target JNK kinases, showcase how specialized inhibition can be tailored to specific kinase families. This specificity is echoed in U0126 and PD98059, which respectively target MEK1/2 and MEK, influencing the ERK pathway Compounds such as LY294002, which inhibits PI3K, demonstrates how the PI3K-Akt pathway can be modulated. In contrast, Rapamycin (Sirolimus) brings attention to mTOR's inhibition and its profound effects on cell growth and proliferation. SB203580's targeting of p38 MAPK gives insights into the modulation of inflammatory responses and cell differentiation. Lastly, BAY 11-7082, an inhibitor of IκBα phosphorylation, brings into focus the modulation of the NF-κB pathways.